Physician profile
Daniel Lin
NPI 1104887421
$7,359.98
in general payments reported to CMS, 2019-2025
30 companies · $1,317 in 2025
The $1,317 reported for 2025 was more than what 91% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $546 · 2020: $685 · 2021: $1,436 · 2022: $1,152 · 2023: $941 · 2024: $1,284 · 2025: $1,317.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,515 · Education: $27.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,514.75 |
| Education | $27.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,311.32 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $556.63 | 2019-2025 | Tavneos, Uplizna, Krystexxa |
| Otsuka America Pharmaceutical, INC. | $546.75 | 2019-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $449.60 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $445.91 | 2019-2024 | Ultomiris |
| Daiichi Sankyo INC. | $437.68 | 2019-2025 | Injectafer |
| Calliditas Therapeutics US INC. | $346.32 | 2022-2025 | Tarpeyo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $293.29 | 2023-2025 | Jardiance |
| Travere Therapeutics, INC. | $275.07 | 2019-2025 | |
| Vifor Pharma, INC. | $263.91 | 2019-2024 | Veltassa |
| Aurinia Pharma U.S., INC. | $253.80 | 2021-2025 | Lupkynis |
| Novo Nordisk INC | $235.43 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Mallinckrodt Hospital Products INC. | $225.64 | 2020-2023 | Acthar |
| Kyowa Kirin, INC. | $210.59 | 2024-2025 | Crysvita |
| Ardelyx, INC. | $199.64 | 2023-2025 | Ibsrela |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biomerieux INC | $180.85 | 2021-2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $175.20 | 2022-2025 | Voyxact, Jynarque |
| Novartis Pharmaceuticals Corporation | $163.34 | 2024-2025 | |
| Glaxosmithkline, LLC. | $145.63 | 2020-2023 | Benlysta |
| Horizon Therapeutics Plc | $110.29 | 2019-2023 | Krystexxa |
| Nxstage Medical, INC. | $94.43 | 2019-2020 | |
| Amag Pharmaceuticals, INC. | $71.98 | 2020-2021 | |
| Mallinckrodt Enterprises LLC | $70.47 | 2019 | |
| Fresenius USA Marketing, INC. | $69.83 | 2019-2025 | Velphoro, Velphoro |
| Pharmacosmos Therapeutics INC. | $61.42 | 2022-2025 | Monoferric |
| Alnylam Pharmaceuticals INC. | $40.16 | 2021-2023 | Givlaari |
| Lilly USA, LLC | $36.37 | 2025 | Zepbound, Mounjaro |
| Opko Pharmaceuticals, LLC | $35.06 | 2021-2025 | Rayaldee |
| Cormedix INC. | $34.33 | 2025 | Defencath |
| Lundbeck LLC | $19.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.